{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:57:43Z","timestamp":1776675463559,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dedicated breast positron emission tomography (dbPET) was developed to detect breast cancers smaller than those detectable using whole-body PET (wbPET). Although several studies have explored the use of dbPET, clear criteria for identifying which patients would benefit most from this modality are lacking. Our objective was to determine which patient groups would benefit most from dbPET and how it should be utilized. We conducted a multicenter, prospective exploratory study to investigate how the dbPET maximum standardized uptake values (SUVmax) correlate with patients\u2019 clinical characteristics, other imaging modalities, and pathological findings of the lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In total, 219 patients with breast cancer (median age [range], 58.0 [30\u201383] years) were included in this study. The enrolled patients were divided into three groups (primary care, neoadjuvant therapy, postoperative follow-up patients). In this research, we examined the primary care group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200992). To investigate which patient groups benefit from dbPET, we examined which factors influence and correlate with dbPET SUVmax. Depending on the items being compared, correlation analysis, Wilcoxon signed rank test was used to examine the following items. Which factors (physical factors, pathological characteristics, etc.) correlate with dbPET SUVmax, differences between dbPET and other imaging examination (detection rate, etc.), and whether dbPET SUVmax L\/H ratio (Lesion-to-Healthy (normal) site dbPET SUVmax ratio) incorporating dbPET SUVmax from healthy (normal) mammary gland tissue are necessary for evaluating dbPET SUVmax in lesion areas.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      dbPET SUVmax in healthy(normal) mammary gland tissue were strongly associated with background mammary density observed on mammography (MMG) examination (positive correlation,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.05). Ki-67 showed the strongest positive correlation with both the lesion-site dbPET SUVmax (r=0.56, R\n                      <jats:sup>2<\/jats:sup>\n                      =0.31,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.05) and the dbPET SUVmax L\/H ratio (lesion-to-healthy (normal) -site ratio) (r=0.47, R\n                      <jats:sup>2<\/jats:sup>\n                      =0.22,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.05). Additionally, the tissue grade, MMG and ultrasonography categories were positively correlated with dbPET SUVmax. Regarding the lesion detection rate, dbPET identified 100% of the lesions, including benign findings. The dbPET SUVmax L\/H ratio showed a trend nearly identical to that of the dbPET SUVmax.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>dbPET demonstrated higher detection capabilities than other imaging tests and showed a strong correlation with tissue malignancy. Therefore, they were suggested to be potentially useful for distinguishing benign findings from malignant lesions that are difficult to differentiate using other imaging tests. The dbPET SUVmax of healthy mammary gland tissue were presumed to correlate with the amount of mammary gland tissue within the breast. However, no significant differences were observed in the correlations between the dbPET values and the L\/H ratio and the individual parameters. In this study, it remained unclear whether the dbPET values of normal breast tissue should be taken into account when evaluating dbPET values.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12880-026-02307-1","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:22:44Z","timestamp":1776673364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multicenter prospective study of dedicated breast positron emission tomography (dbPET) for breast cancer: examination in preoperative patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Youko","family":"Satou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Suga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Yamaguchi Breast Cancer Study Group (YBC)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"2307_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31:1154\u201362. https:\/\/doi.org\/10.1038\/s41591-025-03502-3.","journal-title":"Nat Med"},{"key":"2307_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010.","journal-title":"Breast"},{"key":"2307_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/s1470-2045(25)00017-8","volume":"26","author":"EC Dee","year":"2025","unstructured":"Dee EC, Laversanne M, Bhoo-Pathy N, Ho FDV, Feliciano EJG, Eala MAB, et al. Cancer incidence and mortality estimates in 2022 in Southeast Asia: a comparative analysis. Lancet Oncol. 2025;26:516\u201328. https:\/\/doi.org\/10.1016\/s1470-2045(25)00017-8.","journal-title":"Lancet Oncol"},{"key":"2307_CR4","unstructured":"Cancer Information Service, National cancer center. japan. center for cancer control and information services, national cancer center. 5-1-1 Tsukiji, Chuo-ku, Tokyo 104\u2009\u2013\u20090045, Japan. Telephone: +81-3-3542-2511. https:\/\/ganjoho.jp\/en\/. Accessed on 9 June 2025."},{"key":"2307_CR5","unstructured":"Japanese Society of Nuclear Medicine. \u4e73\u623f\u5c02\u7528 PET \u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 2019 [Guidelines for Dedicated Breast PET 2019]. 1st edition approved 18 October 2019; revised 24 April 2020. PDF, jsnm.org. https:\/\/jsnm.org\/wp_jsnm\/wp-content\/uploads\/2019\/10\/Breast_PET_Guideline2019_200424-1.pdf. Accessed on 9 June 2025."},{"key":"2307_CR6","doi-asserted-by":"publisher","first-page":"21930","DOI":"10.1038\/s41598-020-78865-3","volume":"10","author":"DK Hathi","year":"2020","unstructured":"Hathi DK, Li W, Seo Y, Flavell RR, Kornak J, Franc BL, et al. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET. Sci Rep. 2020;10:21930. https:\/\/doi.org\/10.1038\/s41598-020-78865-3.","journal-title":"Sci Rep"},{"key":"2307_CR7","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s12282-022-01381-x","volume":"29","author":"R Hashimoto","year":"2022","unstructured":"Hashimoto R, Akashi-Tanaka S, Watanabe C, Masuda H, Taruno K, Takamaru T, et al. Diagnostic performance of dedicated breast positron emission tomography. Breast Cancer. 2022;29:1013\u201321. https:\/\/doi.org\/10.1007\/s12282-022-01381-x.","journal-title":"Breast Cancer"},{"key":"2307_CR8","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.ejso.2021.02.026","volume":"47","author":"S Sasada","year":"2021","unstructured":"Sasada S, Kimura Y, Masumoto N, Emi A, Kadoya T, Arihiro K, et al. Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors. Eur J Surg Oncol. 2021;47:1588\u201392. https:\/\/doi.org\/10.1016\/j.ejso.2021.02.026.","journal-title":"Eur J Surg Oncol"},{"key":"2307_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.clinimag.2018.05.010","volume":"51","author":"S Sasada","year":"2018","unstructured":"Sasada S, Masumoto N, Goda N, Kajitani K, Emi A, Kadoya T, et al. Which type of breast cancers is undetectable on ring-type dedicated breast PET? Clin Imaging. 2018;51:186\u201391. https:\/\/doi.org\/10.1016\/j.clinimag.2018.05.010.","journal-title":"Clin Imaging"},{"key":"2307_CR10","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1007\/s00330-019-06106-x","volume":"29","author":"M Bakhshayeshkaram","year":"2019","unstructured":"Bakhshayeshkaram M, Salehi Y, Abbasi M, Hashemi Beni R, Seifi S, Hassanzad M, et al. A preliminary study to propose a diagnostic algorithm for PET\/CT-detected incidental breast lesions: application of BI-RADS lexicon for US in combination with SUVmax. Eur Radiol. 2019;29:5507\u201316. https:\/\/doi.org\/10.1007\/s00330-019-06106-x.","journal-title":"Eur Radiol"},{"key":"2307_CR11","doi-asserted-by":"publisher","first-page":"603303","DOI":"10.3389\/fmed.2020.603303","volume":"7","author":"Y Satoh","year":"2020","unstructured":"Satoh Y, Hirata K, Tamada D, Funayama S, Onishi H. Texture analysis in the diagnosis of primary breast cancer: comparison of high-resolution dedicated breast positron emission tomography (dbPET) and whole-body PET\/CT. Front Med (Lausanne). 2020;7:603303. https:\/\/doi.org\/10.3389\/fmed.2020.603303.","journal-title":"Front Med (Lausanne)"},{"key":"2307_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s12149-023-01846-9","volume":"37","author":"S Yuge","year":"2023","unstructured":"Yuge S, Miyake KK, Ishimori T, Kataoka M, Matsumoto Y, Torii M, et al. Performance of dedicated breast PET in breast cancer screening: comparison with digital mammography plus digital breast tomosynthesis and ultrasound. Ann Nucl Med. 2023;37:479\u201393. https:\/\/doi.org\/10.1007\/s12149-023-01846-9.","journal-title":"Ann Nucl Med"},{"key":"2307_CR13","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.21873\/anticanres.14336","volume":"40","author":"S Sasada","year":"2020","unstructured":"Sasada S, Masumoto N, Kimura Y, Emi A, Kadoya T, Okada M. Classification of abnormal findings on ring-type dedicated breast PET for the detection of breast cancer. Anticancer Res. 2020;40:3491\u20137. https:\/\/doi.org\/10.21873\/anticanres.14336.","journal-title":"Anticancer Res"},{"key":"2307_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2214\/AJR.18.20066","volume":"212","author":"Y Satoh","year":"2019","unstructured":"Satoh Y, Motosugi U, Omiya Y, Onishi H. Unexpected abnormal uptake in the breasts at dedicated breast PET: incidentally detected small cancers or nonmalignant features? AJR Am J Roentgenol. 2019;212:443\u20139. https:\/\/doi.org\/10.2214\/AJR.18.20066.","journal-title":"AJR Am J Roentgenol"},{"key":"2307_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejrad.2018.10.001","volume":"108","author":"L Gra\u00f1a-L\u00f3pez","year":"2018","unstructured":"Gra\u00f1a-L\u00f3pez L, Herranz M, Dom\u00ednguez-Prado I, Argibay S, Villares A, Ruibal A, et al. Dedicated breast PET value to evaluate BI-RADS 4 breast lesions. Eur J Radiol. 2018;108:201\u20137. https:\/\/doi.org\/10.1016\/j.ejrad.2018.10.001.","journal-title":"Eur J Radiol"},{"key":"2307_CR16","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/s41598-022-05166-2","volume":"12","author":"S Sasada","year":"2022","unstructured":"Sasada S, Masumoto N, Emi A, Kadoya T, Okada M. Malignant prediction of incidental findings using ring-type dedicated breast positron emission tomography. Sci Rep. 2022;12:1144. https:\/\/doi.org\/10.1038\/s41598-022-05166-2.","journal-title":"Sci Rep"},{"key":"2307_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ejso.2018.01.014","volume":"44","author":"S Sasada","year":"2018","unstructured":"Sasada S, Masumoto N, Goda N, Kajitani K, Emi A, Kadoya T, et al. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study. Eur J Surg Oncol. 2018;44:444\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2018.01.014.","journal-title":"Eur J Surg Oncol"},{"key":"2307_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10549-021-06179-7","volume":"188","author":"Y Tokuda","year":"2021","unstructured":"Tokuda Y, Yanagawa M, Fujita Y, Honma K, Tanei T, Shimoda M, et al. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI. Breast Cancer Res Treat. 2021;188:107\u201315. https:\/\/doi.org\/10.1007\/s10549-021-06179-7.","journal-title":"Breast Cancer Res Treat"},{"key":"2307_CR19","doi-asserted-by":"publisher","first-page":"e230082","DOI":"10.1148\/rycan.230082","volume":"6","author":"D Diwanji","year":"2024","unstructured":"Diwanji D, Onishi N, Hathi DK, Lawhn-Heath C, Kornak J, Li W, et al. 18F-FDG dedicated breast PET complementary to breast MRI for evaluating early response to neoadjuvant chemotherapy. Rad Imaging Cancer. 2024;6:e230082. https:\/\/doi.org\/10.1148\/rycan.230082.","journal-title":"Rad Imaging Cancer"},{"key":"2307_CR20","doi-asserted-by":"publisher","unstructured":"Mooij de CM, Nijnatten van TJA, G B, K LFS, R IWM, Meijl van SPL, et al. Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F] FDG PET\/MRI in Breast Cancer. Cancers (Basel). 2023;15:401. https:\/\/doi.org\/10.3390\/cancers15020401.","DOI":"10.3390\/cancers15020401"},{"key":"2307_CR21","unstructured":"The Japanese breast cancer society clinical practice guidelines for breast cancer. Japanese breast cancer Soc. https:\/\/jbcs.xsrv.jp\/guideline\/2022\/. Accessed on 9 June 2025."},{"key":"2307_CR22","unstructured":"Japan Radiological Society (JRS). Japanese society of radiological technology. Mammography Guideline 4th. ed. NCID: BC06876214, ISBN, 9784260046220. https:\/\/ci.nii.ac.jp\/ncid\/BC06876214. Accessed on 9 June 2025."},{"key":"2307_CR23","unstructured":"Japan Association of Breast and Thyroid Sonology. Guideline for breast ultrasound: management and diagnosis 4th ed. ISBN: 9784524227631. https:\/\/ci.nii.ac.jp\/ncid\/BC03006395. Accessed on 9 June 2025."},{"key":"2307_CR24","unstructured":"Japanese Breast Cancer Society. Clinical and pathological recording of breast cancer. 18th ed. ISBN: 978430720386. https:\/\/jbcs.xsrv.jp\/guideline\/2022\/b_index\/. Accessed on 9 June 2025."},{"key":"2307_CR25","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s12149-022-01754-4","volume":"36","author":"Y Shimizu","year":"2022","unstructured":"Shimizu Y, Satake H, Ishigaki S, Shimamoto K, Uota F, Tadokoro M, et al. Physiological background parenchymal uptake of 18F-FDG in normal breast tissues using dedicated breast PET: correlation with mammographic breast composition, menopausal status, and menstrual cycle. Ann Nucl Med. 2022;36:728\u201335. https:\/\/doi.org\/10.1007\/s12149-022-01754-4.","journal-title":"Ann Nucl Med"},{"key":"2307_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-023-01492-z","author":"T Imokawa","year":"2023","unstructured":"Imokawa T, Satoh Y, Fujioka T, Takahashi K, Mori M, Kubota K, et al. Deep learning model with collage images for the segmentation of dedicated breast positron emission tomography images. Breast Cancer. 2023. https:\/\/doi.org\/10.1007\/s12282-023-01492-z.","journal-title":"Breast Cancer"},{"key":"2307_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12149-022-01719-7","volume":"36","author":"Y Satoh","year":"2022","unstructured":"Satoh Y, Imokawa T, Fujioka T, Mori M, Yamaga E, Takahashi K, et al. Deep learning for image classification in dedicated breast positron emission tomography (dbPET). Ann Nucl Med. 2022;36:401\u201310. https:\/\/doi.org\/10.1007\/s12149-022-01719-7.","journal-title":"Ann Nucl Med"},{"key":"2307_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/RLU.0000000000005660","volume":"50","author":"Y Kitano","year":"2025","unstructured":"Kitano Y, Miyake KK, Shimizu Y, Kawashima M, Nakamoto Y. Intratumoral Heterogeneity of Primary Breast Cancer on 18 F-FES PET\/CT and dbPET Anticipated a Heterogeneous Response to Chemotherapy. Clin Nucl Med. 2025;50:541\u20133. https:\/\/doi.org\/10.1097\/RLU.0000000000005660.","journal-title":"Clin Nucl Med"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02307-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02307-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02307-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:22:50Z","timestamp":1776673370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-026-02307-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2307"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02307-1","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of each participating institute and was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent for future access and anonymous use of data was obtained from each patient. \u30fbCenter for Clinical Research. Yamaguchi University Hospital IRB No. H2019-123 \u30fbSt. Hill Hospital ethics committee No. R2-008 \u30fbJCHO Tokuyama Central Hospital ethics committee No. K373-20200520 \u30fbNHO Kanmon Medical Center ethics review committee No. R0309-3.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"YBC Group: Representative, Address, and Contact Information.YBC Group Representative: Hiroaki Nagano\n                      1,5\n                      ,YBC Group Adress, Contact Information:\n                      1\n                      Department of Gastroenterological, Breast and Endocrine Surgery, School of Medicine, Yamaguchi University, 1-1-1 Minamikogushi, Ube-shi, Yamaguchi-ken 755\u20138505, Japan.Tel: +81-836-22-2264.E-mail: ges_res@yamaguchi-u.ac.jp,Mari Nabeya\n                      1,5\n                      , Lisa Suyama\n                      1,5\n                      , Yuka Yano\n                      5,6\n                      , Gaku Fukamitsu\n                      5,7\n                      , Takashi Arata\n                      5,8\n                      , Yoshinari Maeda\n                      5,9\n                      , Michinori Iwamura\n                      5,10\n                      , Satoshi Onitsuka\n                      5,11\n                      , Noriko Maeda\n                      1,5\n                      , Yukiko Nagashima\n                      5,12\n                      , Masakazu Fujii\n                      5,13\n                      , Nobuki Matsunami\n                      5,14\n                      , Shigeru Yamamoto\n                      5,15\n                      , Kimikazu Hamano\n                      5,16\n                      , Hiroaki Nagano\n                      1,5\n                      ,\n                      1\n                      Department of Gastroenterological, Breast and Endocrine Surgery, School of Medicine, Yamaguchi University, 1-1-1 Minamikogushi, Ube-shi, Yamaguchi-ken 755\u20138505, Japan.\n                      6\n                      Department of Surgery, Saiseikai Shimonoseki General Hospital, 8-5-1, Yasuokacyo, Shimonoseki-shi, Yamaguchi-ken 759\u20136603, Japan.\n                      7\n                      Fukamitsu Breast Clinic, 3-4-24, Kotobukicyo, Ube-shi, Yamaguchi-ken 755\u2009\u2212\u20090032, Japan.\n                      8\n                      Department of Surgery, National Hospital Organization Iwakuni Clinical Center, 1-1-1, atagocyo, Iwakuni-shi, Yamaguchi-ken 740\u2009\u2212\u20090037, Japan.\n                      9\n                      Department of Surgery, Shunan City Shinnanyo Hospital, 2-3-15, Mianomae, Shunan-shi, Yamaguchi-ken 746\u2009\u2212\u20090017, Japan.\n                      10\n                      Department of Surgery, Yamaguchi Rosai Hospital, 1315-4, Ooazaonoda, Sanyoonoda-shi, Yamaguchi-ken, 756\u2009\u2212\u20090095, Japan.\n                      11\n                      Department of Surgery, Yamaguchi Red Cross Hospital, 53-\u2009\u20091, Yahatababa, Yamaguchi-shi, Yamaguchi-ken 753\u2009\u2212\u20090092, Japan.\n                      12\n                      Department of Breast Surgery, NHO Kanmon Medical Center, 1-1, Cyofusotoura-cyo, Shimonoseki-shi, Yamaguchi-ken 752\u20138510, Japan.\n                      13\n                      Department of Breast Surgery, Yamaguchi Prefectural Grand Medical Center, 10077, Ooazaoosaki, Houfu-shi, Yamaguchi-ken 747\u20138511, Japan.\n                      14\n                      Department of Breast Surgery, Shuto General Hospital, 1000-1, Kogaisaku, Yanai-shi, Yamaguchi-ken 742\u2009\u2212\u20090032, Japan.\n                      15\n                      Department of Breast Surgery, JCHO Tokuyama Central Hospital, 1- 1, Kouda-cho, Syuunann-shi, Yamaguchi-ken 745\u20138522, Japan.\n                      16\n                      Department of Surgery and Clinical Science, School of Medicine, Yamaguchi University, 1-1-1, Minamikogushi, Ube-shi, Yamaguchi-ken 755\u20138505, Japan.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Superscript removed-->5Yamaguchi Breast Cancer Study Group (YBC)"}}],"article-number":"199"}}